Clinical Trial Update: Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating dasatinib in combination with chemotherapy for relapsed acute myeloid leukemia with t(8;21) translocation and KIT D816 mutation. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Translocation

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed AML, T(8;21) | Phase 1 | Status: WITHDRAWN